Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FEMY NASDAQ:ICAD NYSE:INFU NASDAQ:LUCD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFEMYFemasys$0.92-1.0%$0.95$0.69▼$1.80$30.03M-2.56264,678 shs30,984 shsICADicad$3.80+1.9%$3.79$1.19▼$4.02$104.39M1.37419,277 shs94,707 shsINFUInfuSystem$5.53+0.9%$5.94$4.61▼$9.97$116.22M1.81116,103 shs16,700 shsLUCDLucid Diagnostics$1.10-5.8%$1.24$0.72▼$1.80$119.55M1.23696,926 shs1.07 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFEMYFemasys-0.79%+1.36%+4.86%-13.66%-16.74%ICADicad-2.36%+0.27%+1.36%+21.50%+198.40%INFUInfuSystem-2.32%-10.60%-11.76%+10.04%-19.77%LUCDLucid Diagnostics0.00%+10.38%-9.30%+7.34%+32.92%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFEMYFemasys2.8639 of 5 stars3.53.00.00.02.22.50.6ICADicad0.6905 of 5 stars0.05.00.00.01.80.80.0INFUInfuSystem3.1163 of 5 stars2.05.00.00.01.44.21.9LUCDLucid Diagnostics2.5969 of 5 stars3.62.00.00.02.91.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFEMYFemasys 3.00Buy$8.67838.97% UpsideICADicad 2.00HoldN/AN/AINFUInfuSystem 4.00Strong Buy$13.00135.08% UpsideLUCDLucid Diagnostics 3.20Buy$3.55222.14% UpsideCurrent Analyst Ratings BreakdownLatest FEMY, LUCD, INFU, and ICAD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/16/2025LUCDLucid DiagnosticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.006/25/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.006/11/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.006/6/2025LUCDLucid DiagnosticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.50 ➝ $7.755/15/2025LUCDLucid DiagnosticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$2.00 ➝ $2.005/14/2025LUCDLucid DiagnosticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00 ➝ $3.005/13/2025FEMYFemasysJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $6.005/9/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $12.005/8/2025INFUInfuSystemB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/21/2025LUCDLucid DiagnosticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $7.504/17/2025ICADicadLaidlawSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFEMYFemasys$1.63M18.42N/AN/A$0.10 per share9.23ICADicad$19.61M5.32N/AN/A$1.08 per share3.52INFUInfuSystem$137.58M0.84$0.43 per share12.79$2.47 per share2.24LUCDLucid Diagnostics$4.35M27.41N/AN/A($0.78) per share-1.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFEMYFemasys-$18.82M-$0.91N/AN/AN/A-1,242.06%-392.45%-137.15%8/14/2025 (Estimated)ICADicad-$5.62M-$0.19N/A∞N/A-26.63%-15.03%-11.77%8/12/2025 (Estimated)INFUInfuSystem$870K$0.1492.1817.84N/A1.12%2.78%1.41%N/ALUCDLucid Diagnostics-$45.53M-$1.34N/AN/AN/A-1,699.86%N/A-124.27%8/11/2025 (Estimated)Latest FEMY, LUCD, INFU, and ICAD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025ICADicad-$0.0550N/AN/AN/A$4.81 millionN/A8/11/2025Q2 2025LUCDLucid Diagnostics-$0.09N/AN/AN/A$1.15 millionN/A5/13/2025Q1 2025ICADicad-$0.0625-$0.02+$0.0425-$0.03$4.54 million$4.87 million5/8/2025Q1 2025FEMYFemasys-$0.17-$0.23-$0.06-$0.23$1.14 million$0.34 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFEMYFemasysN/AN/AN/AN/AN/AICADicadN/AN/AN/AN/AN/AINFUInfuSystemN/AN/AN/AN/AN/ALUCDLucid DiagnosticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFEMYFemasys0.020.930.54ICADicadN/A3.663.57INFUInfuSystem0.501.981.59LUCDLucid DiagnosticsN/A0.750.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFEMYFemasys65.27%ICADicad24.61%INFUInfuSystem71.13%LUCDLucid Diagnostics74.01%Insider OwnershipCompanyInsider OwnershipFEMYFemasys11.54%ICADicad10.29%INFUInfuSystem11.40%LUCDLucid Diagnostics6.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFEMYFemasys3032.53 million28.77 millionNot OptionableICADicad14027.47 million24.64 millionOptionableINFUInfuSystem41021.02 million19.10 millionOptionableLUCDLucid Diagnostics70108.19 million100.83 millionNo DataFEMY, LUCD, INFU, and ICAD HeadlinesRecent News About These CompaniesLucid Diagnostics' (LUCD) Buy Rating Reaffirmed at Needham & Company LLC4 hours ago | marketbeat.comMolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA TestJuly 16 at 7:31 AM | prnewswire.comBrokerages Set Lucid Diagnostics Inc. (NASDAQ:LUCD) Price Target at $3.55July 16 at 3:57 AM | americanbankingnews.comLucid Diagnostics Inc News (LUCD) - Investing.comJuly 11, 2025 | investing.comLucid Diagnostics Inc. (NASDAQ:LUCD) Receives Average Recommendation of "Buy" from AnalystsJuly 11, 2025 | marketbeat.comMajor California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA TestJune 18, 2025 | prnewswire.comLucid Diagnostics Inc. (NASDAQ:LUCD) Short Interest Down 39.3% in MayJune 16, 2025 | marketbeat.comLucid Diagnostics Inc. (NASDAQ:LUCD) Given Consensus Rating of "Buy" by BrokeragesJune 16, 2025 | marketbeat.comLucid Diagnostics to Join Russell 2000® and Russell 3000® IndexesMay 27, 2025 | prnewswire.comLucid Diagnostics’ SWOT analysis: stock faces reimbursement hurdles amid market potentialMay 21, 2025 | investing.comLucid Diagnostics Reports Increased Losses Amid Revenue DeclineMay 15, 2025 | tipranks.comEarnings call transcript: Lucid Diagnostics Q1 2025 highlights growth and strategic expansionMay 15, 2025 | investing.comPAVmed Provides Business Update and Reports First Quarter 2025 Financial ResultsMay 15, 2025 | prnewswire.comLucid Diagnostics Inc. (LUCD) Q1 2025 Business Update Call TranscriptMay 14, 2025 | seekingalpha.comLucid Diagnostics Inc. (LUCD) Reports Q1 Loss, Lags Revenue EstimatesMay 14, 2025 | zacks.comLucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial ResultsMay 14, 2025 | prnewswire.comWill Lucid Diagnostics Inc. (LUCD) Report Negative Earnings Next Week? What You Should KnowMay 7, 2025 | zacks.comLucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025April 30, 2025 | prnewswire.comLucid Diagnostics’ EsoGuard DNA Test shows cancer detection efficacy in studyApril 26, 2025 | markets.businessinsider.comLucid Diagnostics Reports Positive Data for EsoGuard in Study of Asymptomatic PatientsApril 24, 2025 | theglobeandmail.comLucid reports encouraging results from EsoGuard studyApril 24, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFEMY, LUCD, INFU, and ICAD Company DescriptionsFemasys NASDAQ:FEMY$0.92 -0.01 (-1.02%) As of 01:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.icad NASDAQ:ICAD$3.80 +0.07 (+1.88%) As of 12:56 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.InfuSystem NYSE:INFU$5.53 +0.05 (+0.91%) As of 12:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.Lucid Diagnostics NASDAQ:LUCD$1.10 -0.07 (-5.81%) As of 01:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Delta Air Lines Stock Rallies on New Guidance—Can It Keep Going? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
